A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Clinical trial NCT03017820 · RECRUITING

Trial details

NCT number: NCT03017820
Sponsor: Mayo Clinic
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-Cell Non-Hodgkin Lymphoma Histiocytic and Dendritic Cell Neoplasm Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Recurrent Anaplastic Large Cell Lymphoma Recurrent Angioimmunoblastic T-Cell Lymphoma Recurrent Mycosis Fungoides Recurrent Plasma Cell Myeloma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent T-Cell Non-Hodgkin Lymphoma Refractory Acute Myeloid Leukemia

Start date: 2017-04-04
Primary completion: 2028-12-31
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.